CLDX
Closed
Celldex Therapeutics Inc
21.21
+0.86 (+4.23%)
Last Update: 01 Jul 2025 23:25:00
Yesterday: 20.35
Day's Range: 20.01 - 22.315
Send
sign up or login to leave a comment!
When Written:
35.98
Celldex Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of immunotherapy and targeted therapies for the treatment of cancer and other difficult-to-treat diseases. The company's lead product candidate is CDX-3379, a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) in patients with head and neck squamous cell carcinoma (HNSCC). Celldex also has several other product candidates in clinical development, including CDX-1140, a human monoclonal antibody that targets CD40, and CDX-0159, a humanized monoclonal antibody that targets the KIT receptor. The company was founded in 1983 and is headquartered in Hampton, New Jersey.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








